Despite childhood vaccination efforts and antiviral medications, the rate of hepatitis B infection remains constant in the U.S. with the CDC estimating over 20,000 acute infections each year and over 800,000 people living with chronic HBV infection. The World Health  Organization estimates the global number of chronic HBV infections at over 250 million, with most infections in endemic areas occurring from mother to child at birth before a vaccination can be effective. While antiviral medications can control the replication of the virus, there is currently no cure and life-long antiviral therapy is required to prevent further liver damage and increased cancer risk. Curing this large human reservoir of chronically infected people is crucial to reducing HBV-associated morbidities and mortalities. Seraph Research Institute is spearheading this effort with a novel and proprietary mechanism of action that directly targets the virus at its source and doesn’t simply slow or halt replication like antivirals but actually destroys the viral blueprints in the liver.